Immuron (ASX:IMC), an Australian-based biopharmaceutical company, has announced continued unaudited sales growth for Travelan, its over-the-counter immune supplement targeting pathogenic bacteria in the gastrointestinal tract.
Globally, H1 sales reached $4.2 million, up 5% on the prior comparative period, with Q2 sales of $2.2 million representing an 11% increase on the previous quarter.
In Australia, H1 sales rose 13% to $3.3 million, with Q2 sales up 11% to $1.7 million, supported by the launch of ProIBS prior to Christmas, now stocked by two of the three largest pharmacy wholesalers across five banner groups.
Growth was driven by increased digital marketing, store expansions, promotional activity, and higher South East Asian travel, partially offset by a one-off stock reduction from the Sigma Healthcare/Chemist Warehouse group.
In the US, H1 sales climbed 17% to $0.9 million, with Q2 up 8%, fueled by enhanced Amazon listings, social media campaigns, and influencer engagement.
In Canada, H1 sales declined 85% to $56,000 due to prior-year pipeline fill but rebounded in Q2, rising 191% to $42,000, supported by retail promotions and brand-building initiatives.
Travelan is set to launch in Jean Coutu pharmacies in Quebec in Q3 FY26, further expanding its Canadian presence.
At the time of reporting, Immuron's share price was $0.039.